Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802347 · ClinicalTrials.gov registry record · Phase 1
I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation
A Phase 1 study, sponsored by Quark Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 374
- Enrollment target
NCT00802347: Completed Phase 1 study, sponsored by Quark Pharmaceuticals.
NCT00802347 is a Phase 1 study that has completed, run by Quark Pharmaceuticals. The registered enrollment target is 374 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (523% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00802347, a Phase 1 study, has completed, sponsored by Quark Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 374 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a single administration of QPI-1002 (also known as I5NP) can prevent DGF in patients undergoing deceased donor kidney transplantation. In this Phase I /II study, patients who are undergoing renal transplantation with organs from DCD donors, ECD donors or SCD donors with ≥ 24 hours of cold ischemia time who meet study entry criteria will be studied to evaluate the safety and pharmacokinetic profile of I5NP (Part A) and clinical activity of I5NP administration (Part B). Data from this study will be used to identify doses of I5NP to be used in follow-on efficacy studies. Part A will be a randomized, dose escalation study to determine the highest or maximum tolerated dose (MTD). Part A will enroll 40 patients at approximately 20 sites; patients will be randomized to receive either I5NP or placebo in a ratio of 8:2 in each cohort (cohorts 1-4). Part B will utilize the dose identified in Part A to further evaluate, in a double-blind manner, the safety, and clinical activity of I5NP. In Part B, up to 326 patients will participate at approximately 60 sites; up to 163 patients will be randomized to receive I5NP and up to 163 patients randomized to receive placebo.
Interventions
- DRUG Saline
- DRUG I5NP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT00802347 record still lists
NCT00802347 is an interventional study that assigns participants to a tested intervention. The registered 374 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (523% higher).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT00802347 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00802347 about?
NCT00802347 is a clinical study titled "I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation". The purpose of this study is to determine whether a single administration of QPI-1002 (also known as I5NP) can prevent DGF in patients undergoing deceased donor kidney transplantation. In this Phase I /II study, patients who are undergoing renal transplantation with organs from DCD donors, ECD donor...
What is the current status of trial NCT00802347?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 374 participants. The study started on 2008-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00802347?
The interventions under investigation include: Saline (DRUG), I5NP (DRUG).
Who is sponsoring clinical trial NCT00802347?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00802347's enrollment target sits among peer trials
374 85th of 2000 higher than 1,916 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia